Daniel Hunziker

1.4k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Daniel Hunziker is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Daniel Hunziker has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Organic Chemistry and 5 papers in Pharmacology. Recurrent topics in Daniel Hunziker's work include Microbial Natural Products and Biosynthesis (5 papers), Carbohydrate Chemistry and Synthesis (5 papers) and Peptidase Inhibition and Analysis (4 papers). Daniel Hunziker is often cited by papers focused on Microbial Natural Products and Biosynthesis (5 papers), Carbohydrate Chemistry and Synthesis (5 papers) and Peptidase Inhibition and Analysis (4 papers). Daniel Hunziker collaborates with scholars based in Switzerland, United States and Australia. Daniel Hunziker's co-authors include Chaitan Khosla, David E. Cane, Rajesh S. Gokhale, W. Petter, Albert K. Beck, Dietmar A. Plattner, Yan Ming Wang, Dieter Seebàch, Christian Scheurer and Susan A. Charman and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Microbiology.

In The Last Decade

Daniel Hunziker

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of an antimalarial synthetic trioxolane drug development candidate

2004 507 citations Jonathan L. Vennerstrom, Sarah Arbe‐Barnes et al. Nature profile →

Peers

Countries citing papers authored by Daniel Hunziker

Since Specialization

Citations

This map shows the geographic impact of Daniel Hunziker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Hunziker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Hunziker more than expected).

Fields of papers citing papers by Daniel Hunziker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Hunziker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Hunziker. The network helps show where Daniel Hunziker may publish in the future.

Co-authorship network of co-authors of Daniel Hunziker

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Hunziker. A scholar is included among the top collaborators of Daniel Hunziker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Hunziker. Daniel Hunziker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non‑zinc binding mode 2025 ·Bioorganic & Medicinal Chemistry Letters ·Rainer E. Martin, Alexander L. Satz, (unknown), Daniel Hunziker, Patrizio Mattei, Jérôme Hert, Christoph Ullmer, M.G. Rudolph, André Alker, Remo Hochstrasser, Andreas Marx, (unknown), Stephan Müller	3
2	Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor 2022 ·Frontiers in Pharmacology ·Daniel Hunziker, Sabrina Reinehr, (unknown), Natalie Wagner, (unknown), Gesa Stute, Patrizio Mattei, P Schmitz, (unknown), Jérôme Hert, M.G. Rudolph, J. Benz, M. Stihle, Bernard Gsell, Stephan Müller, Rodolfo Gasser, (unknown), Christoph Ullmer, Stephanie C. Joachim	8
3	Cytochrome P450-Mediated Metabolism and CYP Inhibition for the Synthetic Peroxide Antimalarial OZ439 2021 ·ACS Infectious Diseases ·David M. Shackleford, Francis C. K. Chiu, Kasiram Katneni, (unknown), (unknown), Xiaofang Wang, Lin Zhou, K. Sriraghavan, André Alker, Daniel Hunziker, Christian Scheurer, Qingjie Zhao, Yuxiang Dong, Jörg J. Möhrle, Nada Abla, Hugues Matile, Sergio Wittlin, Jonathan L. Vennerstrom, Susan A. Charman	4
4	Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity 2019 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown), (unknown), (unknown), Daniel Hunziker, Patrizio Mattei, Pratap Challa, Robin Vann, Christoph Ullmer, (unknown)	34
5	Challenges and Rewards in Medicinal Chemistry Targeting Cardiovascular and Metabolic Diseases 2015 ·CHIMIA International Journal for Chemistry ·Werner Neidhart, Tanja Schulz‐Gasch, A. Ruf, Matthias Nettekoven, Hans Peter Märki, Bernd Kuhn, Daniel Hunziker, (unknown), Kurt E. Amrein, (unknown), A. Mayweg	1
6	Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Markus Boehringer, Holger Fischer, Michael Hennig, Daniel Hunziker, Jörg Huwyler, Bernd Kuhn, (unknown), Thomas Luebbers, Patrizio Mattei, Robert Narquizian, E Seböková, Urs Sprecher, Hans Peter Wessel	38
7	Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277 2008 ·Bioorganic & Medicinal Chemistry Letters ·Lin Zhou, André Alker, A. Ruf, Xiaofang Wang, Francis C. K. Chiu, Julia Morizzi, Susan A. Charman, William N. Charman, Christian Scheurer, Sergio Wittlin, Yuxiang Dong, Daniel Hunziker, Jonathan L. Vennerstrom	30
8	1,3-Disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Thomas Lübbers, (unknown), Luca Gobbi, Michael Hennig, Daniel Hunziker, Bernd Kuhn, (unknown), Patrizio Mattei, Robert Narquizian, Jens‐Uwe Peters, Yves Ruff, Hans Peter Wessel, Pierre C. Wyss	30
9	Inhibitors of Dipeptidyl Peptidase IV - Recent Advances and Structural Views 2005 ·Current Topics in Medicinal Chemistry ·Daniel Hunziker, Michael Hennig, Jens‐Uwe Peters	28
10	Stereochemical Assignment of Intermediates in the Rifamycin Biosynthetic Pathway by Precursor-Directed Biosynthesis 2005 ·Journal of the American Chemical Society ·Ingo V. Hartung, Mathew A. Rude, Nathan A. Schnarr, Daniel Hunziker, Chaitan Khosla	11
11	Novel ketolide antibiotics with a fused five-membered lactone ring––synthesis, physicochemical and antimicrobial properties 2004 ·Bioorganic & Medicinal Chemistry ·Daniel Hunziker, (unknown), Peter Angehrn, (unknown), (unknown), (unknown), Laurenz Kellenberger, (unknown), (unknown), Wolf Arnold, Andreas Stämpfli, Anne Schmitt‐Hoffmann, (unknown)	26
12	An aminomethylpyrimidine DPP-IV inhibitor with improved properties 2004 ·Bioorganic & Medicinal Chemistry Letters ·Jens‐Uwe Peters, Daniel Hunziker, Holger Fischer, Manfred Kansy, (unknown), (unknown), (unknown), (unknown), (unknown), Markus Boehringer, Sonia Poli, M. Csató, (unknown)	25
13	Identification of an antimalarial synthetic trioxolane drug development candidate breakdown → 2004 ·Nature ·Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun, Susan A. Charman, Francis C. K. Chiu, Jacques Chollet, Yuxiang Dong, Arnulf Dorn, Daniel Hunziker, Hugues Matile, Kylie A. McIntosh, Maniyan P. Padmanilayam, (unknown), Christian Scheurer, Bernard Scorneaux, Yuanqing Tang, Heinrich Urwyler, Sergio Wittlin, William N. Charman	507
14	The Used of the Internet in Procurement: An Empirical Analysis 2000 ·Journal of the Association for Information Systems ·(unknown), Daniel Hunziker	12
15	Mechanism and specificity of the terminal thioesterase domain from the erythromycin polyketide synthase 1999 ·Chemistry & Biology ·Rajesh S. Gokhale, Daniel Hunziker, David E. Cane, Chaitan Khosla	133
16	A host–vector system for analysis and manipulation of rifamycin polyketide biosynthesis in Amycolatopsis mediterranei 1999 ·Microbiology ·Zhihao Hu, Daniel Hunziker, C. Richard Hutchinson, Chaitan Khosla	11
17	Precursor directed biosynthesis of novel 6-deoxyerythronolide B analogs containing non-natural oxygen substituents and reactive functionalities 1999 ·Tetrahedron Letters ·Daniel Hunziker, Nicholas Wu, (unknown), David E. Cane, Chaitan Khosla	18
18	Primer Unit Specificity in Rifamycin Biosynthesis Principally Resides in the Later Stages of the Biosynthetic Pathway 1998 ·Journal of the American Chemical Society ·Daniel Hunziker, Tin‐Wein Yu, C. Richard Hutchinson, Heinz G. Floss, Chaitan Khosla	37
19	On the Mechanisms of Enantioselective Reactions Using α,α,α′,α′ ‐Tetraaryl‐1,3‐dioxolane‐4,5‐dimethanol(TADDOL)‐Derived Titanates: Differences between C₂‐ and C₁‐symmetrical TADDOLs – facts, implications and generalizations 1992 ·Helvetica Chimica Acta ·Dieter Seebàch, Dietmar A. Plattner, Albert K. Beck, Yan Ming Wang, Daniel Hunziker, W. Petter	189

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact